Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis
作者:Xingping Su、Zui Tan、Guan Wang、Zhihao Liu、Cailing Gan、Lin Yue、Hongyao Liu、Yuting Xie、Yuqin Yao、Tinghong Ye
DOI:10.1016/j.ejmech.2022.114918
日期:2023.1
Herein, based on our previous findings that nifuroxazide (NIF) could effectively attenuate pulmonary fibrosis by inhibiting STAT3 activation, a series of diarylacylhydrazones derivatives have been designed and synthesized. Among them, compounds 44 and 52 could inhibit TGF-β1-induced abnormal activation of NIH-3T3 and A549 cells, as well as migration and EMT of A549 cells. In a bleomycin-induced mouse
特发性肺纤维化(IPF)是一种致命的肺部疾病,其特点是病死率高、病因不明且缺乏有效治疗。许多证据证实抑制 STAT3 的激活是一种有吸引力的 IPF 治疗策略。在此,基于我们之前发现的硝呋恶嗪 (NIF) 可以通过抑制 STAT3 激活有效减轻肺纤维化,我们设计并合成了一系列二芳基酰肼衍生物。其中,化合物44和52可抑制TGF-β1诱导的NIH-3T3和A549细胞的异常活化,以及A549细胞的迁移和EMT。在博来霉素诱导的小鼠肺纤维化模型中,口服给药44和52(生物利用度 F = 31.75% 和 42.08%)改善小鼠肺功能并减缓 IPF 的进展。此外,52可以逆转治疗模型中的肺纤维化。总的来说,这项工作表明44和52可能是治疗 IPF 的潜在先导化合物,值得进一步研究。